d(GC) - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)
32. Contraloría de Panama. XI Censo de
Población y VII de Vivienda, 2010:
Resultados Finales (Volumen V: Migración
y Fecundidad). Cuadro 7. . http://
www.contraloria.gob.pa/inec/
cuadros.aspx?ID=000106 Accessed 31,
Jan 2012
33. Kobayashi, S., Boggon, T.J., Dayaram, T.,
Janne, P.A., Kocher, O., Meyerson, M.,
Johnson, B.E., Eck, M.J., Tenen, D.G., and
Halmos, B. (2005). EGFR mutation and
resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med, 352: 786-92.
34. Bos, J. (1989). ras Oncogenes in Human
Cancer: A Review. Cancer Research, 49:
4682-4689.
35. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A.,
Pan, Q., Ladanyi, M., Zakowski, M.F.,
Heelan, R.T., Kris, M.G., and Varmus, H.E.
(2005). KRAS mutations and primary
resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med, 2: e17.
36. Borras, E., Jurado, I., Hernan, I., Gamundi,
M.J., Dias, M., Marti, I., Mane, B., Arcusa,
A., Agundez, J.A., Blanca, M., and Carballo,
M. (2011). Clinical pharmacogenomic
testing of KRAS, BRAF and EGFR
mutations by high resolution melting
analysis and ultra-deep pyrosequencing.
BMC Cancer, 11: 406.
37. Chen, H.Y., Yu, S.L., Chen, C.H., Chang,
G.C., Chen, C.Y., Yuan, A., Cheng, C.L.,
Wang, C.H., Terng, H.J., Kao, S.F., Chan,
W.K., Li, H.N., Liu, C.C., Singh, S., Chen,
W.J., Chen, J.J., and Yang, P.C. (2007). A
five-gene signature and clinical outcome in
non-small-cell lung cancer. N Engl J Med,
356: 11-20.
38. Hamilton, S. and Aaltonen, L. (2000). World
Health Organization Classification of
Tumours. Pathology and Genetics of
Tumours of the Digestive Tract. , IARC
Press, Lyon, France, pp. 102-143.
Rebecca E. Smith and Juan Miguel Pascale
138
39. Kwak, E.L. and Chung, D.C. (2007).
Hereditary colorectal cancer syndromes: an
overview. Clin Colorectal Cancer, 6: 340-4.
40. National Comprehensive Cancer Network.
Clinical Practice Guidelines in Oncology:
Colorectal Cancer Screening.; http://
www.nccn.org/professionals/physician_gls/
f_guidelines.asp#site Accessed 31, Aug
2011
41. Jasperson, K.W., Tuohy, T.M., Neklason,
D.W., and Burt, R.W. (2010). Hereditary
and familial colon cancer. Gastroenterology,
138: 2044-58.
42. Kohlmann, W. and Gruber, S.B. Lynch
Syndrome. http://www.ncbi.nlm.nih.gov/
books/NBK1211/ Accessed 31, Jan 2012
43. Alonso-Espinaco, V., Giraldez, M.D.,
Trujillo, C., van der Klift, H., Munoz, J.,
Balaguer, F., Ocana, T., Madrigal, I., Jones,
A.M., Echeverry, M.M., Velez, A.,
Tomlinson, I., Mila, M., Wijnen, J., Carvajal-
Carmona, L., Castells, A., and Castellvi-Bel,
S. (2011). Novel MLH1 duplication identified
in Colombian families with Lynch syndrome.
Genet Med, 13: 155-60.
44. Giraldo, A., Gomez, A., Salguero, G.,
Garcia, H., Aristizabal, F., Gutierrez, O.,
Angel, L.A., Padron, J., Martinez, C.,
Martinez, H., Malaver, O., Florez, L., and
Barvo, R. (2005). MLH1 and MSH2
mutations in Colombian families with
hereditary nonpolyposis colorectal cancer
(Lynch syndrome)—description of four
novel mutations. Fam Cancer, 4: 285-90.
45. Gomez, A., Salguero, G., Garcia, H.,
Aristizabal, F., Gutierrez, O., Angel, L.A.,
Padron, J., Martinez, C., Martinez, H.,
Malaver, O., Barvo, R., and Giraldo, A.
(2005). Detection mutations in the DNA
mismatch repair genes of hMLH1 and
hMSH2 genes in Colombian families with
suspicion of hereditary non-polyposis
colorectal carcinoma (Lynch syndrome).
Biomedica, 25: 315-24.